Sign In
Buy CHRS
$1.46
-0.0200 (-1.35%)
At Close: Jun 23, 2026
Coherus Oncology: Setting Up For Important Readouts In Mid-2026
06:00am, Wednesday, 13'th May 2026
Coherus Oncology (CHRS) remains a Buy as I maintain optimism around its advancing immunotherapy pipeline despite recent market negativity. Key catalysts include mid-2026 data readouts for casdozokitug
Coherus Oncology, Inc. (CHRS) Q1 2026 Earnings Call Transcript
09:50am, Tuesday, 12'th May 2026
Coherus Oncology, Inc. (CHRS) Q1 2026 Earnings Call Transcript
Coherus Oncology Q1 Earnings Call Highlights
07:07pm, Monday, 11'th May 2026
Coherus Oncology NASDAQ: CHRS said it expects revenue growth for its nasopharyngeal cancer drug LOQTORZI to build through the rest of 2026, while the company prepares for multiple clinical data readou
Coherus Oncology (CHRS) Reports Q1 Loss, Lags Revenue Estimates
07:06pm, Monday, 11'th May 2026
Coherus Oncology (CHRS) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.35 per share a year ago.
Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update
04:05pm, Monday, 11'th May 2026
– LOQTORZI® net revenue of $11.8 million in Q1 2026 – – Patient accrual complete for 1L HCC Phase 2 randomized clinical trial for anti-IL27 casdozokitug, timing for data readouts tracking to pr
Pre-Market Stock Futures: Futures are trading mixed as we get set to start the new trading week, as reports indicate that President Trump declined Iran's counteroffer for peace. This comes after a rem
Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026
09:30am, Monday, 04'th May 2026
REDWOOD CITY, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its first quarter 2026 financial results will be released after market close on Mond
Coherus Oncology (CHRS) Upgraded to Buy: Here's What You Should Know
01:01pm, Wednesday, 25'th Mar 2026
Coherus Oncology (CHRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Coherus Oncology, Inc. (NASDAQ:CHRS) Receives $5.51 Consensus Target Price from Brokerages
01:40am, Monday, 16'th Mar 2026
Shares of Coherus Oncology, Inc. (NASDAQ: CHRS - Get Free Report) have received an average rating of "Hold" from the five ratings firms that are currently covering the stock, Marketbeat Ratings report
Coherus Oncology, Inc. (CHRS) Q4 2025 Earnings Call Transcript
08:57pm, Monday, 09'th Mar 2026
Coherus Oncology, Inc. (CHRS) Q4 2025 Earnings Call Transcript
Coherus Oncology (CHRS) Reports Q4 Loss, Misses Revenue Estimates
06:36pm, Monday, 09'th Mar 2026
Coherus Oncology (CHRS) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.28 per share a year ago.
Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update
04:15pm, Monday, 09'th Mar 2026
– LOQTORZI® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 – – Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 �
Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026
09:30am, Monday, 02'nd Mar 2026
REDWOOD CITY, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its full year and fourth quarter 2025 financial results will be released after mark
Coherus Oncology to Participate in Upcoming Investor Conferences
09:30am, Monday, 23'rd Feb 2026
REDWOOD CITY, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that senior management will be presenting during upcoming conferences. The presentations w
Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock
04:11pm, Tuesday, 17'th Feb 2026
–The Offering was led by healthcare-dedicated investors including Janus Henderson Investors, HBM Healthcare Investments and Samsara BioCapital–
